This study not only corroborates the oncogenic roles of DLEU1, HIF-1α, and CKAP2, but also justifies the potential of targeting these molecules in the treatment of breast cancers, particularly those associated with higher malignancy and worse prognosis. The gene discussed is HIF1A; the disease is breast carcinoma.